‘Extensively Drug Resistant’ Illness Is Spreading Through the US: ‘There Are No CDC Recommendations’

On Friday, the CDC issued an ominous advisory about the rise of an “extensively drug resistant” stomach bug in the United States.

The health advisory, which was issued mid-day Friday, warned about a spike in shigellosis across the United States.

While shigellosis and the Shigella infections have been known for some time now, it was only recently that drug-resistant (XDR) strains began popping up on the CDC’s radar.

“In 2022, about 5 percent of Shigella infections reported to CDC were caused by XDR strains, compared with 0 percent in 2015,” the CDC said in its advisory.

The CDC then warned that doctors have “limited antimicrobial treatment options” due to the resistant nature of the infections.

Trending:

Massive Migrant Caravan Marches Toward US with LGBT Flags Flying as Mexican President Snubs Biden at Summit

Compounding that matter, the CDC warned that Shigella bacteria is “easily transmissible.”

“Given these potentially serious public health concerns, CDC asks healthcare professionals to be vigilant about suspecting and reporting cases of XDR Shigella infection to their local or state health department and educating patients and communities at increased risk about prevention and transmission.”

“Shigella bacteria are transmitted by the fecal-oral route, directly through person-to-person contact including sexual contact, and indirectly through contaminated food, water, and other routes,” the CDC added.

Further along in the advisory, under the section labeled “Clinical Management,” the CDC doubled down on the relative hopelessness of the situation due to the strain’s drug-resistant nature.

Do you trust the CDC?

Yes: 0% (0 Votes)

No: 0% (0 Votes)

“To date, there are no CDC recommendations for treating XDR shigellosis in the United States,” the CDC stated.

The CDC did follow that up with an interesting tidbit that there have been some positive studies to come out of the United Kingdom, but with some major caveats.

Chief among those caveats, one of the drugs that has shown promise in helping deal with XDR shigellosis (“oral pivmecillinam”) is not commercially available for use in the United States.

Interestingly, the CDC noted that while shigellosis has historically been an issue for young children (ages 1 to 4), there are now some very specific subsets of people who are also at an increased…

Source